Colorectal Cancer Incidence Increasing in Younger Adults
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
Colorectal Cancer
Postsurgical ctDNA Levels May Predict Disease Recurrence in Colorectal Cancer
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
Oral Aspirin Does Not Up FIT Test Sensitivity for ID’ing CRC
Administration of a single dose of oral aspirin prior to fecal immunochemical testing does not increase test sensitivity for detecting advanced colorectal neoplasms.
MRI Selects “Good Prognosis” Rectal Cancer Patients for Primary Surgery
Rectal cancer patients with good tumor prognosis according to magnetic resonance imaging criteria may not need preoperative chemoradiotherapy.
No OS Benefit of Immunotherapy Plus MEK Inhibitor for Patients With Microsatellite-Stable Metastatic Colorectal Cancer
RAS tumor status was not predictive of benefit from the combination of atezolizumab and cobimetinib compared with regorafenib.
Cardiorespiratory Fitness Tied to Lower Risk for Lung Cancer, CRC
Higher cardiorespiratory fitness (CRF) is associated with a lower risk for incident lung and colorectal cancer and with a lower risk for all-cause mortality among those diagnosed with lung and colorectal cancer.
Limited Clinical Benefit for the Combination of TRC102 and Temozolomide in Refractory Colorectal Cancer
The median number of prior treatments for patients with relapsed colorectal cancer enrolled in this phase 2 study was 6.
COLOMATE: Using a Liquid Biopsy in CRC to Select a Molecularly Targeted Therapy
The companion study arms under the COLOMATE trial umbrella will include those that specifically enroll patients with HER2-amplified or EGFR-mutant disease.
Colorectal Cancer Pathogenesis May Be Driven by Alterations in MACROD2
The appearance of structural variants in MACROD2, culled from sequencing data from patients with colorectal cancer, may be a hallmark of CRC pathogenesis.
Pertuzumab Plus Trastuzumab in HER2-Amplified Metastatic Colorectal Cancer: Evidence For Promising Activity
Most patients with HER2-amplified colorectal cancer who achieved a response to pertuzumab plus trastuzumab had disease characterized as KRAS wild-type.
Next post in Gastrointestinal Cancers
